Skip to main content
Fig. 6 | Molecular Neurodegeneration

Fig. 6

From: SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease

Fig. 6

shRNA-mediated knock down of SETD7 expression reduces meK130 and mek132-modified Tau in SHSY5Y cells. A Representative Western blots and quantification demonstrate a strong reduction of SETD7 protein in SHSY5Y cells treated with shRNA. B meK132-modified Tau is absent in SH-SY5Y cells treated with shRNA against SETD7, representative Western blots and quantification. C Representative Western blots and quantification demonstrate that shRNA against SETD7 also reduces the levels of meK130-modified Tau in SH-SY5Y cells, albeit to a smaller degree than the meK132 modification. D Transient transfection of WT, K130R and K132R mutant Tau 2N4R into HEK cells demonstrates that the K132R mutation significantly decreases meK130-modified Tau levels. Representative Western blots and quantification are shown. Statistical significance in (A), (B) and (C) was determined by Mann Whitney test, **: p < 0.01. Statistical significance in (D) was determined by one-way ANOVA (ANOVA p < 0.0001), Tukey’s multiple comparisons test was used for post-hoc analysis. *: p < 0.05, **: p < 0.01, ****: p < 0.0001

Back to article page